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Development of a Multifunctional Benzophenone Linker
for Peptide Stapling and Photoaffinity Labelling
Yuteng Wu+,[a] Lasse B. Olsen+,[a] Yu Heng Lau+,[a] Claus Hatt Jensen,[a] Maxim Rossmann,[b]
Ysobel R. Baker,[a] Hannah F. Sore,[a] Sﬄil Collins,[a] and David R. Spring*[a]
Photoaffinity labelling is a useful method for studying how
proteins interact with ligands and biomolecules, and can help
identify and characterise new targets for the development of
new therapeutics. We present the design and synthesis of a
novel multifunctional benzophenone linker that serves as both
a photo-crosslinking motif and a peptide stapling reagent.
Using double-click stapling, we attached the benzophenone to
the peptide via the staple linker, rather than by modifying the
peptide sequence with a photo-crosslinking amino acid. When
applied to a p53-derived peptide, the resulting photoreactive
stapled peptide was able to preferentially crosslink with MDM2
in the presence of competing protein. This multifunctional
linker also features an extra alkyne handle for downstream ap-
plications such as pull-down assays, and can be used to inves-
tigate the target selectivity of stapled peptides.
Protein–protein interactions (PPIs) are inextricably involved in
a host of cellular functions, with aberrant activity linked to a va-
riety of human diseases.[1] Tool compounds that can probe spe-
cific PPIs are vital for unravelling the functions of individual
proteins within a complex protein network, and can potentially
identify and characterise new targets for drug development.[2]
In particular, compounds that can be used for photoaffinity la-
belling are powerful tools for studying the interactions of pro-
teins with ligands or other biomolecules.[3] Photoaffinity label-
ling involves the use of a photoactivatable functionality that,
on exposure to UV light, can form a covalent linkage to bio-
molecules within close proximity.[4] This irreversible process en-
ables subsequent analysis of the interaction.[5]
As part of our work on stapled peptides to inhibit PPIs, we
were interested in developing photoaffinity tools to character-
ise our peptides and their target PPIs. In peptide stapling,
a promising strategy for designing a-helix mimetic inhibitors,
two amino acid side-chains are joined to form a macrocycle.[6]
Non-proteogenic amino acids are commonly used for macrocy-
lisation; however, techniques involving all native residues are
also available.[7] The resulting peptide is stabilised in a helical
conformation, which can lead to improved binding affinity and
pharmacokinetic properties, relative to those of the linear ana-
logues.[8] Walensky and co-workers used photoaffinity probes
to covalently trap proteins in the BH3/BCL2 complex by incor-
porating unnatural benzophenone-bearing amino acids into
hydrocarbon-stapled BH3 peptides.[9]
We have previously reported a double-click stapling tech-
nique where the peptide and linker are two separate compo-
nents. This allowed facile modification of the linker to tailor
the reactivity of the overall stapled peptide.[8b,10]
In this study, we sought to incorporate a photoactive benzo-
phenone moiety into the stapling linker itself. By installing the
photoactive group in the linker the peptide sequence is not
modified, thus possibly minimising disruption of the overall
binding affinity. We reasoned that combining double-click sta-
pling groups with photoaffinity labelling within one linker
could provide a rapid means of assessing the target selectivity
of stapled peptides as well as the identification of potential
off-target interactions. In addition to the double-click stapling
motif and photoactivatable group, we also designed an extra
protected alkyne handle for downstream applications such as
pull-down assays (Scheme 1). As a proof of concept, we ap-
plied our photolabelling linker to a p53 peptide for binding
MDM2, a PPI that has received significant attention in anti-
cancer therapeutics. Overexpression of the E3 ubiquitin ligase
MDM2 in some cancer cell lines leads to loss of function of
p53, a crucial tumour suppressor protein.[11] This in turn can
result in uncontrolled abnormal cell growth and subsequent
cancer progression.
Scheme 1. Multifunctional linker with two alkynes for double-click stapling
(black), a benzophenone group for photo-crosslinking (blue), and an addi-
tional protected alkyne handle for pull-down assays (red).
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The novel benzophenone linker 1 was synthesised in four
steps (Scheme 2), commencing with a Sonogashira coupling of
(commercially available) 3,5-dibromobenzaldehyde (2) with tri-
methylsilylacetylene to give the bis-TMS-protected intermedi-
ate 3 in good yield. Deprotection of the acetylene groups
under basic conditions resulted in the dialkyne intermediate 4.
Nucleophilic addition with pre-prepared (4-((trimethylsilyl)eth-
ylnyl)phenyl)lithium reagent afforded the secondary alcohol 6.
Oxidation of the alcohol with Dess–Martin periodinane (DMP)
gave the final dialkynyl benzophenone linker 1 in an overall
yield of 12% for the four-step synthesis.
In order to synthesise the photoactive stapled peptide, we
followed our previously reported, optimised copper-catalysed
double-click method with a peptide sequence (A0) derived
from an alpha-helix in the N-terminal transactivation domain
of p53.[8b,10, 12] This approach involved the installation of azide-
containing non-natural amino acids at defined positions (i,
i+7) within the peptide sequence. These azide functionalities
were then reacted with the bis-alkyne-benzophenone linking
unit 1 by copper catalysis. Formation of the TMS-protected sta-
pled peptide product was seen initially (Figure S2 in the Sup-
porting Information). Subsequently, full TMS deprotection was
observed after six hours under the click-reaction conditions to
yield the desired photoaffinity probe A1 in one step
(Scheme 3, Table 1).
We envisioned that incorporation of a biotin moiety would
facilitate future pull-down experiments, so a test click reaction
of A1 with commercially available biotin-PEG3-azide was car-
ried out (Scheme 3). The click reaction generated the expected
tris-triazole product C cleanly, as monitored by HPLC and LCMS
(see Sections 2 and 5 in the Supporting Information).
Isothermal calorimetry experiments were carried out to test
whether our synthesised photoaffinity probe A1 achieved
binding affinity comparable to that of similar stapled ana-
logues (e.g. , the non-TAMRA-labelled A0 sequence stapled
with 1.3-diethynylbenzene; Kd=6.72.8 nm).[8b, 10] The binding
affinity of A1 for MDM2 was 186 nm, thus suggesting that
the staple modification did not significantly impact target
binding. We also synthesised an F3A negative control B1,
which was significantly less potent as a result of mutating one
of the key binding residues to alanine.
Scheme 2. Four-step synthesis of benzophenone stapling linker 1. DMP:
Dess–Martin periodinane. a) TMS-CCH, Pd(PPh3)4, CuI, Et3N, THF, RT, 24 h
(76%); b) NaOH, THF, 0 8C, 3 h (81%); c) nBuLi; d) 4, THF, ¢78 8C, 16 h (31%
over two steps) ; e) DMP, CH2Cl2, RT, 2 h (64%).
Scheme 3. Copper-catalysed double-click stapling and attachment of
a biotin-PEG3 pull-down handle onto the resulting stapled peptide. a) 1,
CuSO4·5H2O, THPTA, sodium l-ascorbate, tBuOH/H2O (1:1), RT, 6 h (46%);
b) CuSO4·5H2O, THPTA, sodium l-ascorbate, tBuOH/H2O (1:1), RT, 6 h (full
conversion by HPLC).
Table 1. In vitro binding affinity of photoactive stapled peptides for
MDM2 by isothermal calorimetry.
Peptide Sequence Kd [nm]
A1 TAMRA-Ahx-ETF-Orn(N3)-DLWRLL-Orn(N3)-EN-NH2 186
B1(F3A) TAMRA-Ahx-ETA-Orn(N3)-DLWRLL-Orn(N3)-EN-NH2 480240
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The crosslinking ability of A1 was investigated by incubation
with recombinant MDM2. Upon UV irradiation at 365 nm, suc-
cessful crosslinking to MDM2 was observed by in-gel fluores-
cence of the TAMRA label after SDS-PAGE (Figure 1). A1 cross-
linking was time-dependent over the course of an hour, where-
as B1 (F3A control peptide) showed no crosslinking to the
target (Section S7).
In order to determine if the observed crosslinking was spe-
cific for MDM2, A1 was incubated with mixtures of MDM2 and
bovine serum albumin (BSA). Clear bands reflected preferential
labelling of MDM2 by A1 (not B1), and the addition of BSA did
not significantly impact the ability of A1 to crosslink to MDM2
(Figure 2).
In summary, we designed and synthesised a novel multifunc-
tional linker to serve as both a peptide stapling reagent and
a photoaffinity probe with pulldown capability. The benzophe-
none linker successfully underwent copper-catalysed double-
click stapling to generate A1. Subsequent reaction of the ter-
minal alkyne on the linker with a biotinylated azide demon-
strated the potential to carry out pull-down assays with the
probe. The binding affinity of the stapled probe was compara-
ble to those of previously studied p53 stapled peptides. Finally,
the probe effectively crosslinked with MDM2 after UV irradia-
tion, and the crosslinking was specific for MDM2 over compet-
ing BSA. This methodology is currently limited to labelling pu-
rified protein and known PPIs. The next step is MDM2 labelling
and pulldown in cell lysate or live cells. We envisage that this
linker strategy could be applied to study other PPIs and their
corresponding peptidic inhibitors.
Experimental Section
Linker synthesis: 3,5-Dibromobenzaldehyde (2) and ((4-bromophe-
nyl)ethynyl)trimethylsilane 5 were purchased from Sigma–Aldrich.
3,5-Bis((trimethylsilyl)ethynyl)benzaldehyde (3)[13] and 3,5-diethynyl-
benzaldehyde (4)[14] were synthesised as previously reported.
(3,5-Diethynylphenyl)(4-((trimethylsilyl)ethynyl)phenyl)methanol
(6): nBuLi (1.6m in hexanes, 11.9 mL, 19.0 mmol) was added drop-
wise over 10 min to a stirring solution of 5 (3.44 g, 13.7 mmol) in
dry THF (40 mL) at ¢78 8C under N2. The mixture was stirred for
30 min, then 4 (969 mg, 6.29 mmol) in dry THF (20 mL) was added
dropwise. The reaction mixture was allowed to warm to RT and
stirred for 16 h. H2O (30 mL) was added, and the two phases were
separated. The aqueous phase was extracted with Et2O (3Õ50 mL).
The combined organic extracts were dried over MgSO4, filtered
and concentrated in vacuo. The residue was purified by column
chromatography (petroleum ether/EtOAc, 20:1) to give the product
(640 mg, 31%) as a clear oil. 1H NMR (400 MHz, CDCl3): d=7.50–
7.49 (m, 1H), 7.45–7.41 (m, 4H), 7.28–7.24 (m, 2H), 5.71 (s, 1H),
3.09 (s, 2H), 0.25 ppm (s, 9H); 13C NMR (100 MHz, CDCl3): d=144.1,
143.2, 143.6, 132.1, 130.4, 128.4, 126.3, 122.5, 104.7, 94.5, 82.4, 78.1,
74.8, ¢0.2 ppm; IR (neat): n˜=3291, 2957, 2155, 1587, 1506, 1249,
1043 cm¢1; HRMS (m/z) for C22H20OSi: calcd: 311.1256
[M+H¢H2O]+ , found: 311.1269.
(3,5-Diethynylphenyl)(4-((trimethylsilyl)ethynyl)phenyl)metha-
none (1): A solution of 6 (205 mg, 0.627 mmol) in dry CH2Cl2
(2 mL) was added dropwise to a stirring suspension of DMP
(318 mg, 0.750 mmol) in dry CH2Cl2 (2 mL) at RT under N2. The re-
action mixture was stirred for 2 h. NaHCO3 (10% aq.) saturated
with Na2S2O3 (15 mL) was added, and the mixture was extracted
with EtOAc (3Õ50 mL). The combined organic phase was washed
with NaHCO3 (10%) saturated with Na2S2O3 (3Õ50 mL), dried over
MgSO4, filtered and concentrated in vacuo. The residue was puri-
fied by column chromatography (petroleum ether/EtOAc, 20:1) to
give the product (130 mg, 64%) as a white solid. M.p. : 109–110 8C;
1H NMR (400 MHz, CDCl3): d=7.83 (d, J=1.5 Hz, 2H), 7.80 (t, J=
1.5 Hz, 1H), 7.75–7.72 (m, 2H), 7.61–7.58 (m, 2H), 3.17 (s, 2H),
0.29 ppm (s, 9H); 13C NMR (100 MHz, CDCl3): d=193.9, 138.7, 137.8,
135.9, 133.2, 131.9, 129.8, 127.9, 123.0, 103.8, 98.4, 81.5, 79.2,
¢0.2 ppm; IR (neat): n˜=3280, 3065, 2959, 2156, 1656, 1599, 1311,
1221 cm¢1; HRMS (m/z) for C22H18OSi: calcd: 327.1205 [M+H]
+ ,
found: 327.1210.
Double-click stapling:[8b,10] A prepared solution of copper(II) sul-
fate pentahydrate (1 equiv), tris(3-hydroxypropyltriazolylmethyl)a-
mine (1 equiv) and sodium ascorbate (3.0 equiv) in degassed water
was added to a stirring solution of the diazido peptide (1.0 equiv;
1 mLmg¢1) and dialkynyl linker 1 (1.1 equiv) in degassed tert-buta-
nol/water (1:1) at RT under N2. The reaction mixture was stirred for
6 h, lypohilised and purified by HPLC to give the final stapled pep-
tide. The reaction between A1 (1 equiv) and biotin-PEG3-azide
(1.2 equiv; Sigma–Aldrich) was carried out under the same click
conditions.
Figure 1. Photoaffinity labelling of MDM2 (170 mm) with A1 (1 mm), visualised
by in-gel fluorescence and InstantBlue protein staining (note: band intensi-
ties are not directly comparable between the two images). See the Support-
ing Information for F3A control ; full gels in Figure S7.
Figure 2. Photoaffinity labelling of MDM2 in the presence of BSA. MDM2 is
preferentially labelled by peptide A1; control peptide B1 does not label
MDM2. BSA was at 170 mm (+) or 240 mm (++).
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HPLC analysis and purification: Analytical HPLC was performed
on a 1260 Infinity LC System (Agilent Technologies) with a SUPEL-
COSIL ABZ+Plus column (150 mmÕ4.6 mm, 3 mm) and linear gra-
dient elution (solvent A: TFA (0.05%, v/v) in water; solvent B: TFA
(0.05%, v/v) in acetonitrile; 1 mLmin¢1). Semipreparative HPLC was
performed on the 1260 Infinity with a SUPELCOSIL ABZ+Plus
column (250 mmÕ21.2 mm, 5 mm) and linear gradient elution (sol-
vent A: TFA (0.1%, v/v) in water; solvent B: TFA (0.05%, v/v) in ace-
tonitrile; 20 mLmin¢1). HPLC was monitored by UV absorbance at
555 nm.
Preparation of recombinant MDM2: The expression plasmid for
MDM2 (6-125), kindly provided by Dr Anasuya Chattopadhyay (De-
partment of Pharmacology, University of Cambridge), was trans-
formed into Escherichia coli C41 competent cells.[12] Cells were
grown in 2TY medium with ampicillin at 37 8C to OD600=0.6, then
induced with IPTG (0.5 mm) overnight at 25 8C. The cells were pel-
leted, resuspended in ice-cold buffer A (Tris·HCl (50 mm, pH 8.0),
NaCl (500 mm), DTT (5 mm), EDTA (1 mm), Triton X-100 (0.1%, v/v),
EDTA-free protease inhibitors (Roche)) and lysed with an Emulsiflex
C5 homogeniser (Glen Creston). Lysate was bound onto gluta-
thione Sepharose 4B beads (GE Healthcare) for 1 h at 4 8C. The
beads were washed with buffer B (buffer A without Triton X-100 or
protease inhibitors), then cleaved on-resin with PreScission pro-
tease (GE Healthcare) overnight at 4 8C. The cleaved protein was
purified by gel filtration (HiLoad 16/60 Superdex G75; GE Health-
care). Protein identity, purity and concentration were determined
by amino acid analysis.
Isothermal calorimetry: Calorimetric titrations were performed on
a MicroCal ITC200 (Malvern Instruments, Malvern, UK). Protein and
peptides were exchanged into buffer containing Na2HPO4 (50 mm),
KH2PO4 (10 mm, pH 7.4), NaCl (137 mm), KCl (2.7 mm), TCEP
(0.5 mm), P20 surfactant (0.005%) and DMSO (2%). The titration ex-
periments were performed at 21 8C with an initial injection (0.4 mL,
duration 0.8 s) followed by 19 injections (2 mL, 4 s) at 120 s spacing.
For the binding assays, MDM2 (50 mm) was titrated into peptide so-
lution (5 mm). Binding isotherms were fit by non-linear regression
with the single-site model provided in Origin software (MicroCal,
Inc. OriginLab, Northampton, MA). The stoichiometry of the inter-
action (N), equilibrium association constant (Ka) and change of en-
thalpy (DH) were allowed to vary during the fitting.
Photoaffinity labelling of recombinant MDM2: A mixture of ben-
zophenone stapled peptide A1 or B1 (0.1 nmol) and recombinant
MDM2 (17 nmol) in Tris buffer (100 mL) was incubated for 15 min at
RT, and then irradiated at 365 nm in a Longwave Ultraviolet Cross-
linker (model CL-1000 L; UVP, Upland, CA) for the indicated time.
Irradiated samples were analysed by SDS-PAGE on 4–20% tricine
gels (Expedeon, San Diego, CA) and visualised by in-gel fluores-
cence imaging in a Typhoon FLA 9500 (555 nm; GE Healthcare)
and InstantBlue protein staining (Expedeon). Binding specificity ex-
periments with BSA (Fraction V, pH 7.0; GE Healthcare) were per-
formed as above with the indicated concentrations of BSA in PBS
buffer.
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